Cargando…
Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness
Cholangiocarcinoma (CCA) is the second most common primary liver malignancy with extremely poor therapeutic outcome due to high drug resistance, widespread metastasis and lack of effective treatment options. CCA progression and metastasis are regulated by multiple biological factors including multip...
Autores principales: | Xie, Ying, Wang, Yazhe, Li, Jing, Hang, Yu, Jaramillo, Lee, Wehrkamp, Cody J., Phillippi, Mary Anne, Mohr, Ashley M., Chen, Yi, Talmon, Geoffrey A., Mott, Justin L., Oupický, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134930/ https://www.ncbi.nlm.nih.gov/pubmed/30214622 http://dx.doi.org/10.7150/thno.26506 |
Ejemplares similares
-
XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells
por: Wehrkamp, Cody J., et al.
Publicado: (2014) -
FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis
por: Natarajan, Sathish Kumar, et al.
Publicado: (2017) -
Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells
por: Silakit, Runglawan, et al.
Publicado: (2018) -
MicroRNA-210 downregulates TET2 and contributes to inflammatory response in neonatal hypoxic-ischemic brain injury
por: Ma, Qingyi, et al.
Publicado: (2021) -
Neuroprotective Effects of MicroRNA-210 on Hypoxic-Ischemic Encephalopathy
por: Qiu, Jie, et al.
Publicado: (2013)